Molecular pathways: The role of primary cilia in cancer progression and therapeutics with a focus on hedgehog signaling

Nadia B. Hassounah, Thomas A. Bunch, Kimberly McDermott

Research output: Contribution to journalArticle

80 Citations (Scopus)

Abstract

Abnormal Hedgehog (Hh) pathway activity has been reported in many cancers, including basal cell carcinomas, medulloblastomas, rhabdomyosarcomas, glioblastomas, and breast and prostate cancers. For this reason, the Hh pathway is a flourishing area for development of anticancer drugs such as Hh ligand antagonists (e.g., 5E1 and robotnikinin), Smo inhibitors (e.g., GDC-0449 and IPI-926), and Gli transcriptional activity inhibitors (e.g., GANT58 and GANT61). It is now clear that primary cilia are required for activation of the Hh pathway in normal vertebrate cells. It is in the primary cilium that both positive and negative effectors of the Hh pathway are processed by posttranslational modifications. In many cancers, preliminary results suggest that primary cilia are lost. As drugs that inhibit different steps of the Hh pathway are developed, it will be important to consider howthese drugs will function in the context of primary cilia in the tumor environment. Here, we discuss why some of the Hh inhibitors may be ineffective if primary cilia are lost on cancer cells. Understanding the relationships between clinical inhibitors of the Hh pathway and the presence or absence of primary cilia may turn out to be critical for targeting these therapeutics to the correct population of patients and improving their efficacy. Further work is needed in this area to maximize the potential of these exciting therapeutic targets.

Original languageEnglish (US)
Pages (from-to)2429-2435
Number of pages7
JournalClinical Cancer Research
Volume18
Issue number9
DOIs
StatePublished - May 1 2012

Fingerprint

Hedgehogs
Cilia
Neoplasms
Therapeutics
HhAntag691
Pharmaceutical Preparations
Medulloblastoma
Rhabdomyosarcoma
Basal Cell Carcinoma
Post Translational Protein Processing
Glioblastoma
Vertebrates
Prostatic Neoplasms
Breast Neoplasms
Ligands

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Molecular pathways : The role of primary cilia in cancer progression and therapeutics with a focus on hedgehog signaling. / Hassounah, Nadia B.; Bunch, Thomas A.; McDermott, Kimberly.

In: Clinical Cancer Research, Vol. 18, No. 9, 01.05.2012, p. 2429-2435.

Research output: Contribution to journalArticle

@article{fd7d8ec099c64b93bddd46a2b6d29c7c,
title = "Molecular pathways: The role of primary cilia in cancer progression and therapeutics with a focus on hedgehog signaling",
abstract = "Abnormal Hedgehog (Hh) pathway activity has been reported in many cancers, including basal cell carcinomas, medulloblastomas, rhabdomyosarcomas, glioblastomas, and breast and prostate cancers. For this reason, the Hh pathway is a flourishing area for development of anticancer drugs such as Hh ligand antagonists (e.g., 5E1 and robotnikinin), Smo inhibitors (e.g., GDC-0449 and IPI-926), and Gli transcriptional activity inhibitors (e.g., GANT58 and GANT61). It is now clear that primary cilia are required for activation of the Hh pathway in normal vertebrate cells. It is in the primary cilium that both positive and negative effectors of the Hh pathway are processed by posttranslational modifications. In many cancers, preliminary results suggest that primary cilia are lost. As drugs that inhibit different steps of the Hh pathway are developed, it will be important to consider howthese drugs will function in the context of primary cilia in the tumor environment. Here, we discuss why some of the Hh inhibitors may be ineffective if primary cilia are lost on cancer cells. Understanding the relationships between clinical inhibitors of the Hh pathway and the presence or absence of primary cilia may turn out to be critical for targeting these therapeutics to the correct population of patients and improving their efficacy. Further work is needed in this area to maximize the potential of these exciting therapeutic targets.",
author = "Hassounah, {Nadia B.} and Bunch, {Thomas A.} and Kimberly McDermott",
year = "2012",
month = "5",
day = "1",
doi = "10.1158/1078-0432.CCR-11-0755",
language = "English (US)",
volume = "18",
pages = "2429--2435",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "9",

}

TY - JOUR

T1 - Molecular pathways

T2 - The role of primary cilia in cancer progression and therapeutics with a focus on hedgehog signaling

AU - Hassounah, Nadia B.

AU - Bunch, Thomas A.

AU - McDermott, Kimberly

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Abnormal Hedgehog (Hh) pathway activity has been reported in many cancers, including basal cell carcinomas, medulloblastomas, rhabdomyosarcomas, glioblastomas, and breast and prostate cancers. For this reason, the Hh pathway is a flourishing area for development of anticancer drugs such as Hh ligand antagonists (e.g., 5E1 and robotnikinin), Smo inhibitors (e.g., GDC-0449 and IPI-926), and Gli transcriptional activity inhibitors (e.g., GANT58 and GANT61). It is now clear that primary cilia are required for activation of the Hh pathway in normal vertebrate cells. It is in the primary cilium that both positive and negative effectors of the Hh pathway are processed by posttranslational modifications. In many cancers, preliminary results suggest that primary cilia are lost. As drugs that inhibit different steps of the Hh pathway are developed, it will be important to consider howthese drugs will function in the context of primary cilia in the tumor environment. Here, we discuss why some of the Hh inhibitors may be ineffective if primary cilia are lost on cancer cells. Understanding the relationships between clinical inhibitors of the Hh pathway and the presence or absence of primary cilia may turn out to be critical for targeting these therapeutics to the correct population of patients and improving their efficacy. Further work is needed in this area to maximize the potential of these exciting therapeutic targets.

AB - Abnormal Hedgehog (Hh) pathway activity has been reported in many cancers, including basal cell carcinomas, medulloblastomas, rhabdomyosarcomas, glioblastomas, and breast and prostate cancers. For this reason, the Hh pathway is a flourishing area for development of anticancer drugs such as Hh ligand antagonists (e.g., 5E1 and robotnikinin), Smo inhibitors (e.g., GDC-0449 and IPI-926), and Gli transcriptional activity inhibitors (e.g., GANT58 and GANT61). It is now clear that primary cilia are required for activation of the Hh pathway in normal vertebrate cells. It is in the primary cilium that both positive and negative effectors of the Hh pathway are processed by posttranslational modifications. In many cancers, preliminary results suggest that primary cilia are lost. As drugs that inhibit different steps of the Hh pathway are developed, it will be important to consider howthese drugs will function in the context of primary cilia in the tumor environment. Here, we discuss why some of the Hh inhibitors may be ineffective if primary cilia are lost on cancer cells. Understanding the relationships between clinical inhibitors of the Hh pathway and the presence or absence of primary cilia may turn out to be critical for targeting these therapeutics to the correct population of patients and improving their efficacy. Further work is needed in this area to maximize the potential of these exciting therapeutic targets.

UR - http://www.scopus.com/inward/record.url?scp=84860536549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860536549&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-11-0755

DO - 10.1158/1078-0432.CCR-11-0755

M3 - Article

C2 - 22415315

AN - SCOPUS:84860536549

VL - 18

SP - 2429

EP - 2435

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 9

ER -